Who is in your network?

📣 In June 2021, Novartis International AG announced receiving approval from the US Food & Drug Administration (FDA) for the Breakthrough Therapy Designation (BTD) to 177Lu-PSMA-617 in patients with conditions of metastatic castration-resistant prostate cancer (mCRPC).

▶️ 𝐕𝐢𝐞𝐰 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭 𝐰𝐢𝐭𝐡 𝐋𝐚𝐭𝐞𝐬𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:- https://www.marknteladvisors.c....om/research-library/

#prostate_cancer_market #prostatecancer #cancer #biopharma #ultrasound #tumor #healthcare #marknteladvisors #marketresearch

Computed Tomography (CT) scans are swiftly gaining traction for ovarian cancer diagnosis, owing to their capabilities to create detailed pictures of areas inside the body.

▶️ 𝐒𝐩𝐞𝐚𝐤 𝐭𝐨 𝐭𝐡𝐞 𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐟𝐨𝐫 𝐦𝐨𝐫𝐞 𝐝𝐞𝐭𝐚𝐢𝐥𝐬:- https://www.marknteladvisors.c....om/query/talk-to-our

#ovarian_cancer_market #ovariancancer #cancer #gynecologic #drugdiscovery #oncology #tumor #healthcare #marketresearch #marknteladvisors

Asia-Pacific is anticipated to demonstrate the fastest market growth in the coming years, principally due to the mounting focus of governments of different countries in the region on developing the robust healthcare infrastructure, especially oncology, including Non-Small Cell Lung Cancer.

▶️ 𝐆𝐞𝐭 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭:- https://www.marknteladvisors.c....om/research-library/

#non_small_cell_lung_cancer_market #lungcancer #biopharma #drugdiscovery #oncology #chemotherapy #asiapacific #marketresearch #healthcare #marknteladvisors

In May 2022, FDA granted accelerated approval to Kymriah, tisagenlecleucel, developed by Novartis Pharmaceuticals Corporation, for adult patients with relapsed or refractory FL (Follicular Lymphoma) post at least two lines of systemic therapy.

▶️ 𝐀𝐜𝐜𝐞𝐬𝐬 𝐅𝐮𝐥𝐥 𝐒𝐮𝐦𝐦𝐚𝐫𝐲: - https://www.marknteladvisors.c....om/research-library/

#non_hodgkin_lymphoma_market #lymphoma #immunotherapy #therapy #pharmaceuticals #bloodcancer #marketresearch #marknteladvisors #healthcare

In March 2022, FDA approved Opdualag, i.e., a combination of immune checkpoint inhibitors, Nivolumab & Relatlimab-rmbw, for patients aged 12 years or older with unresectable or metastatic melanoma. Both drugs block proteins on immune cells, which, in turn, releases the immune response against cancer cells.

▶️ 𝐒𝐩𝐞𝐚𝐤 𝐭𝐨 𝐭𝐡𝐞 𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐟𝐨𝐫 𝐦𝐨𝐫𝐞 𝐝𝐞𝐭𝐚𝐢𝐥𝐬: - https://lnkd.in/dQxvbzmw

#malignant_melanoma_market #tumour #cancer #allergies #melanoma #biopsy #drugs #healthcare #marketresearch #marknteladvisors